Dr. John Cush RheumNow
5 years 1 month ago
Highly allergic can safely get the COVID Vax. Israeli study of 8102 pts w/ allergies recv Pfizer mRNA vax - 429 were highly allergic-->98% of the highly allergic had no allergic rxns, 1% mild allergic resp & 3 anaphylactic rxns Rx w/ EPI, none hospitalized https://t.co/ATYs5R5AQC https://t.co/RoYU2vVLl2
FDA JAK inhibitor warnings and what it means (also: what do you think?); other news released this week; and, two questions submitted from listeners. Dr. Cush discusses this and more in this week's podcast.
Dr. John Cush RheumNow
5 years 1 month ago
Did you know that we have large library of downloads available for use in education? Head to RheumNow and download today.
https://t.co/CEbS8eDs1j https://t.co/VTJWYUrm8U
Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT) had lower SARS-CoV-2 vaccine antibody responses.
Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied to baricitinib and upadacitinib.
Dr. John Cush RheumNow
5 years 1 month ago
I need to correct this tweet. there have NOT YET Been any changes to the PI for Xeljanz. What is highlighted here is the language prior to yesterdays FDA action. The Companies will have to work w/ FDA on changing the boxed warning. My Mistake! https://t.co/ymp1MMiLOd
Dr. John Cush RheumNow
5 years 1 month ago
Using inpatient hospital records of 1.9 million SLE pts, the mortality of hospitalized #SLE changed little from 2006-2016; mortality dropped from 2.2% to 1.5% - with most of this decline between 2006-2008 and no change since. Racial disparities seen. https://t.co/UUsJYFxQS4
Dr. John Cush RheumNow
5 years 1 month ago
Steroid (GC) discontinuation from the BeSt and IMPROVED trials shows that w/ GC d/c 40% of RA pts Flare and 50-60% restart GC. Similar outcomes w/ 2nd attempt at GC d/c. Lower DAS28 scores had better odds of GC D/C. https://t.co/PtbgONNMwW
Dr. John Cush RheumNow
5 years 1 month ago
Lancet: 1276 Wuhan hosp COVID-19 pts studied at 6 & 12 mos. 68% & 49% had at least 1 COVID Sx at 6 & 12 mos. 12 mos sxs: SOB (30%), depression(26%), pain & mobility. Women had more fatigue/weak (OR 1.43), anx/depression (2·0), diffusion impairment (2·97) https://t.co/A8STTYiHq5 https://t.co/J4JoKFa00K
Dr. John Cush RheumNow
5 years 1 month ago
The FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.
https://t.co/jayl8ufPHn https://t.co/zNvPiVcdOM
Dr. John Cush RheumNow
5 years 1 month ago
500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RC3Cph https://t.co/jMsuUM9lWy
Dr. John Cush RheumNow
5 years 1 month ago
In 2018-2019 Australia spent $136 billion on healthcare with more spent on MSK disorders ($14 billion) than CV Dz ($11.8 billion), cancer ($11.8 billion) & mental Dz ($10.5 billion). CAD, back pain, dementia, COPD & lung cancer caused most $$ burden. https://t.co/WHIPeNGIhf
Dr. John Cush RheumNow
5 years 1 month ago
Newly Revised Xeljanz Boxed Warning. New Changes highlighted in yellow. https://t.co/jayl8tYeiN https://t.co/5tXX00UgBD
